TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30887764
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive pill (OCP)
Study: 9124829
Drug: Foscarnet (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet (intravenous dosages for 10 days)
Study: 1425160
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy (6-20 IU at bedtime plus oral drugs)
Study: 6737950
Drug: Human growth
Normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human growth hormone (12 U hGH/m2 per week)
Study: 30393077
Drug: Baseline dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline dietary intake assessment using Automated Self‐Administered 24‐Hour Recall; participants reported food intake on 3 nonconsecutive days.
Study: 29762043
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil 1.6 g/day for 12 weeks
Study: 24040856
Drug: Ephedrine (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine (0.02 mg×kg‐1×min‐1)
Study: 24040856
Drug: Phenylephrine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (0.25 μg×kg‐1×min‐1)
Study: 18178070
Drug: ITRA‐GSMP capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITRA‐GSMP capsule (50mg itraconazole)
Study: 17000452
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg pilocarpine (Salagen) four times daily for 12 weeks
Study: 14525814
Drug: Statistical process
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statistical process control methods applied to analyze medication errors
Study: 11038436
Drug: Celgene thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Celgene thalidomide capsules (200 mg) under fasted conditions
Study: 11038436
Drug: Celgene thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Celgene thalidomide capsules (200 mg) with food
Study: 11038436
Drug: Serral thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Serral thalidomide tablets (200 mg) under fasted conditions
Study: 7768585
Drug: Losartan potassium
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan potassium 25 mg
Study: 21029622
Drug: Drug eluting
Normalized name: Drug eluting stent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug eluting stent
Study: 998673
Drug: Full-course radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-course radiation therapy
Study: 16375890
Drug: Delta(9)‐THC 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delta(9)‐THC 5 mg orally
Study: 16375890
Drug: Morphine 0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.02 mg/kg intravenously
Study: 30802419
Drug: Vortioxetine (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine (10-20 mg/day)
Study: 22967863
Drug: Oral minocycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral minocycline and artificial tears
Study: 12232493
Drug: Control (spa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (spa therapy)
Study: 17727882
Drug: Desipramine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine treatment
Study: 22985610
Drug: Amiodarone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (600 mg the night before surgery and 400 mg twice daily for 4 to 6 days post-surgery)
Study: 17985384
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose intracoronary adenosine
Study: 471857
Drug: i.v. domperidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. domperidone (0.35 and 0.7 mg/kg)
Study: 30795749
Drug: Exposure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure therapy
Study: 27803094
Drug: Sbv (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sbv (20 mg/kg/d for 20 days)
Study: 15101068
Drug: Guided self‐help
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided self‐help (self‐help manual with a maximum of 18 short weekly visits)
Study: 15101068
Drug: Cognitive-behavioral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral group therapy (CBT) (18 weekly 1.5‐h sessions)
Study: 9677215
Drug: Selegiline (alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline (alone or in combination with levodopa)
Study: 27324883
Drug: Balneotherapy (sulfur
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balneotherapy (sulfur bath) combined with home exercise therapy
Study: 27324883
Drug: Home exercise
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home exercise therapy alone
Study: 20046519
Drug: azasetron 10
Normalized name: Azasetron
DrugBank: Azasetron (DB16837)
Approvals — FDA: no, EMA: no, PMDA: no
Description: azasetron 10 mg (group A)
Study: 6309461
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg enalapril once daily
Study: 6309461
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg enalapril twice daily
Study: 31771921
Drug: Recommended Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended Daily Allowance level of protein (0.8 g protein/kg BW)
Study: 29023803
Drug: Tenofovir (TDF)
Normalized name: emtricitabine/tenofovir (TDF) 200 mg-300 mg ORAL TABLET
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir (TDF) therapy for 384 weeks
Study: 29023803
Drug: HBeAg decline
Normalized name: HBSAG
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBeAg decline ≥2.2 log10 PEIU/mL at week 24
Study: 21960535
Drug: Levosimendan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (40 μg/kg bolus followed by 0.1/0.2 μg/kg/min continuous infusion)
Study: 11231941
Drug: Rofecoxib, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib, 50 mg once daily for 5 days
Study: 8614706
Drug: flesinoxan (5-HT1A
Approvals — FDA: no, EMA: no, PMDA: no
Description: flesinoxan (5-HT1A agonist)
Study: 1002852
Drug: Therapy for
Normalized name: nutritional therapy for GSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy for /s/‐defective children, 1 hour per week for 5 weeks.
Study: 1002852
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (control group).
Study: 29471855
Drug: 16 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 sessions of EMDR therapy
Study: 24637663
Drug: Chronic menthol
Normalized name: Menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic menthol capsule treatment
Study: 23123230
Drug: Flurizan (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurizan (a γ‐secretase modulator)
Study: 19105409
Drug: Mildronate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mildronate (1 g/day) with basic anti‐diabetic treatment and alpha‐lipoic acid for 3 months
Study: 8983936
Drug: New tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: New tablet formulation of carbamazepine (400 mg single oral dose)
Study: 27687820
Drug: Solifenacin (5mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin (5mg, titrated to optimum dose)
Study: 14738830
Drug: Whitening gel
Normalized name: HYDROGEN PEROXIDE 2.8 g in 100 g TOPICAL GEL [Luzen Whitening Gel]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whitening gel containing 6% hydrogen peroxide
Study: 11404532
Drug: Triple drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple drug therapy (zidovudine 300 mg or 200 mg for body weight <60 kg, lamivudine 150 mg, didanosine 200 mg or 125 mg for body weight <60 kg)
Study: 11404532
Drug: Double drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double drug therapy
Study: 11404532
Drug: Triple drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple drug therapy
Study: 9404926
Drug: Low-dose G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose G-CSF (50 microg/m2/day)
Study: 9404926
Drug: Standard-dose G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose G-CSF (5 microg/kg/day, approximately 200 microg/m2/day)
Study: 9404926
Drug: Standard-dose G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose G-CSF (5 microg/kg/day)
Study: 24513849
Drug: 1.4 g
Normalized name: MENTHOL 1.4 g in 100 g TOPICAL CREAM [Cetilar]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.4 g XOS
Study: 24513849
Drug: 2.8 g
Normalized name: glycerin 2.8 GM per 2.7 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.8 g XOS
Study: 22809107
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy (2,500 Lux) for 1 week
Study: 18500187
Drug: Tramadol 1
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 1 mg/kg in 10 mL 0.9% normal saline
Study: 18500187
Drug: Bupivacaine 10
Normalized name: BUPivacaine 100 mg parenteral implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 10 mL of 0.25%
Study: 11704073
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of hydrocortisone
Study: 7958669
Drug: Complete amino
Normalized name: Complete Amino Acid Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete amino acid solution containing the dipeptide L‐alanyl‐L‐glutamine (20 g/L)
Study: 20671376
Drug: Other antiplatelet
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antiplatelet aggregation drugs
Study: 11283125
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous cytarabine (Ara-C) added to high-dose intravenous methotrexate (MTX)
Study: 8504271
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (PGE) (Prostin E2, 0.5 mg per tablet)
Study: 29848422
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia (0.5% proparacaine hydrochloride, pledget soaked, applied 3 minutes before surgery)
Study: 25662557
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy (red laser)
Study: 25662557
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy (infrared laser)
Study: 18572153
Drug: Huperzine A
Normalized name: Huperzine A
DrugBank: Huperzine A (DB04864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huperzine A (100, 200, 300, and 400 microg doses, twice daily for a week at each dose)
Study: 14697809
Drug: Tacrolimus and
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus and basiliximab (steroid-free)
Study: 14697809
Drug: Tacrolimus and
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus and steroids (historical control)
Study: 16181747
Drug: Amoxicillin (AMX)
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin (AMX)
Study: 24285642
Drug: Successful treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful treatment of insomnia
Study: 22700830
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal conjugate vaccine (PCV-7) administered to all residents in 11 villages.
Study: 20399326
Drug: Exenatide +
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide + lifestyle modification program (5 microg twice daily, increased to 10 microg after 4 weeks)
Study: 17943589
Drug: Intravenous patient‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient‐controlled analgesia (IV‐PCA)
Study: 17943589
Drug: Intramuscular analgesics
Normalized name: ANALGESIC CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular analgesics (meperidine)
Study: 11991427
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment with reassurance, a well-fitted brassiere, caffeine reduction, and primrose oil
Study: 11991427
Drug: Medications such
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications such as danazol, bromocriptine, and tamoxifen
Study: 11991427
Drug: Future studies
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Future studies should include selective-serotonin reuptake inhibitors and primrose oil
Study: 22216503
Drug: Bumetanide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide (1 mg)
Study: 7287241
Drug: Tienilic acid
Normalized name: Tienilic acid
DrugBank: Tienilic acid (DB04831)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tienilic acid (250 mg)
Study: 6756707
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg daily/6 days)
Study: 24115138
Drug: Cholecalciferol 1600
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 1600 IU and calcium carbonate 1000 mg (D+)
Study: 18095197
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg gabapentin
Study: 21493417
Drug: Midazolam 50
Normalized name: midazolam 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 50 µg/kg
Study: 21493417
Drug: Midazolam 75
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam 75 µg/kg
Study: 21493417
Drug: Midazolam 50
Normalized name: midazolam 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 50 µg/kg and Midazolam 75 µg/kg
Study: 19458163
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of methotrexate (MTX) and sulfasalazine (SSZ) in patients naïve to both drugs
Study: 28249119
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL blueberry concentrate providing 387 mg anthocyanidins
Study: 25129453
Drug: Treatment buddying
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment buddying
Study: 25129453
Drug: Treatment buddying
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment buddying with PAS
Study: 21200360
Drug: MenACWY-DT vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-DT vaccine (Control)
Study: 22704725
Drug: MenACWY-TT vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-TT vaccine
Study: 18086463
Drug: PUFA supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUFA supplement (eicosapentanoic acid (EPA) plus docosahexanoic acid (DHA), 2.2 mg/day in a 3:2 ratio)
Study: 10673513
Drug: Doxorubicin (second-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (second-line therapy after cross-over)
Study: 6548867
Drug: CMF chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF chemotherapy for 1 year (group A)
Study: 6548867
Drug: CMF chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF chemotherapy for 1 year and postoperative radiation therapy (group B)
Study: 29504415
Drug: Naloxegol (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxegol (12.5 and/or 25 mg)
Study: 29504415
Drug: Naloxegol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxegol (all doses)
Study: 25118129
Drug: Counseling for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counseling for the family (one counseling session from a nurse) plus treatment-as-usual for the patient
Study: 25118129
Drug: Family psychoeducation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family psychoeducation (four, two-hour biweekly multifamily psychoeducation sessions) plus treatment-as-usual for the patient (consultation by physicians)
Study: 23571150
Drug: High-dose infusional
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose infusional 5-fluorouracil (HD-FU)
Study: 12821733
Drug: IV ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ceftriaxone 2 g daily for 30 days followed by oral doxycycline 200 mg daily for 60 days
Study: 9375752
Drug: G-CSF (0.3-3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (0.3-3.0 microg/kg/d, s.c.) and epo (60-300 U/kg/d, s.c.) for at least 10 weeks
Study: 9375752
Drug: G-CSF plus
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF plus epo
Study: 9375752
Drug: Predictive scoring
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predictive scoring system based on pre-treatment serum epo levels and RBC transfusion need
Study: 30980122
Drug: Tiopronin or
Normalized name: tiopronin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiopronin or D-penicillamine at 2 g/day
Study: 30980122
Drug: Tiopronin or
Normalized name: tiopronin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiopronin or D-penicillamine at 3 g/day
Study: 30284393
Drug: Nepafenac (Nevanac,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nepafenac (Nevanac, 1 mg/ml) for 3 weeks
Study: 22136324
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro with recombinant human hyaluronidase (rHuPH20)
Study: 18511355
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day vitamin K1
Study: 11686812
Drug: Powered toothbrush
Normalized name: Pro Clean Spinbrush Powered Toothbrush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powered toothbrush (Braun Oral‐B 3D Plaque Remover)
Study: 7929695
Drug: High-dose IL-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IL-1 alpha (3.0 micrograms/m2/day)
Study: 7929695
Drug: Low-dose IL-1
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IL-1 alpha (0.1, 0.3, or 1.0 microgram/m2/day)
Study: 7929695
Drug: High-dose IL-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IL-1 alpha
Study: 7929695
Drug: Low-dose IL-1
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IL-1 alpha
Study: 29635419
Drug: BCG vaccine
Normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccine in children with non-BCG-vaccinated mothers
Study: 29635419
Drug: BCG vaccine
Normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccine in children born by cesarean section
Study: 26923690
Drug: Placebo ultrasound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ultrasound treatment and exercise therapy
Study: 22034523
Drug: Peppermint spirits
Normalized name: Peppermint
DrugBank: Peppermint (DB10984)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peppermint spirits inhalation
Study: 19733206
Drug: 0.61% green
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.61% green tea extract solution (OM24, 100% Camellia Sinensis leaf extract, catechin concentration: 30+/‐3%, pH 7.0, Omnimedica, Switzerland)
Study: 11907288
Drug: Fluconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (200 mg daily for six weeks)
Study: 1495854
Drug: Exogenous surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous surfactant therapy
Study: 2404097
Drug: Sham (air)
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham (air) therapy
Study: 27432356
Drug: COBRA Classic
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: COBRA Classic (MTX + sulfasalazine + prednisone step-down from 60 mg)
Study: 27432356
Drug: COBRA Slim
Normalized name: benzalkonium chloride Topical Foam [DigiClean Slim-Line]
Approvals — FDA: no, EMA: no, PMDA: no
Description: COBRA Slim (MTX + prednisone step-down from 30 mg) high risk
Study: 27432356
Drug: COBRA Avant
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: COBRA Avant Garde (MTX + leflunomide + prednisone step-down from 30 mg)
Study: 21867532
Drug: Neuromuscular Electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neuromuscular Electrical Stimulation (NMES) Therapy
Study: 19152514
Drug: 20% ALA-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% ALA-based photodynamic therapy (PDT) applied for 4 hours, followed by excimer-dye laser exposure at 630 nm at a dose of 50 J/cm² three times at 7-day intervals.
Study: 9571555
Drug: Topical aqueous
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical aqueous indomethacin
Study: 22289547
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml normal saline
Study: 22289547
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml normal saline containing adrenaline (5 μg/ml)
Study: 16672731
Drug: Three-factor solution
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-factor solution (somatic, affective, and cognitive)
Study: 7956269
Drug: Good description
Approvals — FDA: no, EMA: no, PMDA: no
Description: Good description (G) of assignment methods
Study: 30643079
Drug: Dabigatran 150
Normalized name: dabigatran 150 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 150 mg dual therapy
Study: 26446728
Drug: Drug-Coated Balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-Coated Balloon Angioplasty (DCBA)
Study: 17020889
Drug: Drug-eluting stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stents (sirolimus or paclitaxel-eluting)
Study: 22675955
Drug: Tenoxicam 20
Normalized name: tenoxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 20 mg